Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis

BACKGROUND: ABP 710 is being developed as a biosimilar to infliximab reference product (RP). Analytical similarity and pharmacokinetic equivalence between the two have been previously demonstrated. Here we report results from a comparative clinical study that evaluated the efficacy and safety of ABP...

Descripción completa

Detalles Bibliográficos
Autores principales: Genovese, Mark C., Sanchez-Burson, Juan, Oh, MyungShin, Balazs, Eva, Neal, Jeffrey, Everding, Andrea, Hala, Tomas, Wojciechowski, Rafal, Fanjiang, Gary, Cohen, Stanley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098142/
https://www.ncbi.nlm.nih.gov/pubmed/32216829
http://dx.doi.org/10.1186/s13075-020-2142-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098142/
https://www.ncbi.nlm.nih.gov/pubmed/32216829
http://dx.doi.org/10.1186/s13075-020-2142-1

Ejemplares similares